According to the World Health Organization, about 422 million people worldwide have diabetes, and 1.5 million deaths are directly attributed to it each year. To better understand the nuances and factors contributing to the disease and its complications, IHH Malaysia became the first Platinum Sponsor of the Seremban Diabetes (SeDia) Cohort Study in Malaysia, with a contribution of RM 2 million.
Jean-François Naa, CEO of IHH Malaysia, presented a mock cheque at the launch of the longitudinal study by the Ministry of Health and International Medical University on 08 July 2023.
The SeDia Cohort Study will encompass a comprehensive examination of various factors, from genetics and family history of diabetes to lifestyle and environmental factors, dietary regimes, physical activity, socio-economic levels and healthcare delivery. By understanding the complex connections between these factors, the aim is to uncover optimal strategies for diabetes prevention and treatment.
Subsequently, this knowledge can be translated into evidence-based public healthcare policies and programmes that are relevant to the local community. This ensures the efficacy of developed treatment and prevention initiatives in addressing the escalating burden of diabetes in Malaysia.
This 12-year study marks the first important step towards obtaining data that is socio-culturally relevant to the local community. It involves over 5,000 patients registered as part of the Klinik Kesihatan Seremban’s Diabetes Registry and over 7,000 of their family members, to investigate the complex web of interactions that contribute to the development of diabetes and its complications.
Related Stories
IHH Healthcare Deepens Commitment to Reduce Cancer Burden in Malaysia
Learn how our third memorandum of understanding with Ministry of Health Malaysia is expanding access to life-saving, advanced cancer care at 8 of our hospitals.
IHH Healthcare Bags Four Wins at the 15th Asian Excellence Awards
Celebrating our leadership, sustainability, and investor relations excellence on the regional stage.
Fortis CEO Shares Vision for a Healthier India on NDTV
Here is a look at how Fortis is contributing to India’s healthcare transformation.
IHH Singapore Hits New Digital and Imaging Milestones
Across Singapore, IHH Healthcare is transforming care delivery through data, technology and frontline innovation.
Parkway Radiology Deploys Annalise.ai Chest X-ray AI Solution
Parkway Radiology has implemented the Annalise.ai Enterprise CXR solution across all its radiology clinics and hospital departments in Singapore. This represents the first network-wide deployment of the chest X-ray AI technology in the country.
Fortis Enhances Diagnostic and Paediatric Care at S L Raheja Hospital, Mumbai
S L Raheja Hospital, a Fortis Associate, has significantly expanded its diagnostic and paediatric capabilities with the launch of AI-enabled Digital Positron Emission Tomography–Computed Tomography (PET-CT), 3 Tesla Magnetic Resonance Imaging (MRI), and upgraded Neonatal Intensive Care Unit (NICU) and Paediatric Intensive Care Unit (PICU) services.
